March 11 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS PROVIDES UPDATE ON TIMING OF TOPLINE RESULTS FOR PHASE 2B/3 COVID-19 TRIAL OF IFENPRODIL
* ALGERNON PHARMACEUTICALS - EXPECTS TO REPORT TOPLINE RESULTS FOR PHASE 2B PART OF PHASE 2B/3 COVID-19 TRIAL OF IFENPRODIL, IN LAST WEEK OF MARCH 2021